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BACKROUND: The target substrates of DNA mismatch recognising factors MutSa (MSH2þMSH6) and MutSb (MSH2þMSH3) have
already been widely researched. However, the extent of their functional redundancy and clinical substance remains unclear. Mismatch
repair (MMR)-deficient tumours are strongly associated with microsatellite instability (MSI) and the degree and type of MSI seem to
be dependent on the MMR gene affected, and is linked to its substrate specificities. Deficiency in MSH2 and MSH6 is associated with
both mononucleotide and dinucleotide repeat instability. Although no pathogenic MSH3 mutations have been reported, its deficiency
is also suggested to cause low dinucleotide repeat instability.
METHODS: To assess the substrate specificities and functionality of MutSa and MutSb we performed an in vitro MMR assay using three
substrate constructs, GT mismatch, 1 and 2 nucleotide insertion/deletion loops (IDLs) in three different cell lines.
RESULTS: Our results show that though MutSa alone seems to be responsible for GT and IDL1 repair, MutSa and MutSb indeed have
functional redundancy in IDL2 repair and in contrast with earlier studies, MutSb seems to exceed MutSa.
CONCLUSION: The finding is clinically relevant because the strong role of MutSb in IDL2 repair indicates MSH3 deficiency in tumours
with low dinucleotide and no mononucleotide repeat instability.
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The five proteins involved in the human mismatch repair (MMR)
mechanism to maintain genomic integrity function as hetero-
dimers are MutLa (MLH1þPMS2), MutSa (MSH2þMSH6) and
MutSb (MSH2þMSH3). MMR proteins correct base/base mis-
matches and small insertion/deletion loops (IDLs) that arise on the
newly synthesised strand during DNA replication and recombina-
tion. Larger loop structures (X5nt) are believed to require a
different combination of repair proteins and hence are not targets
of the MMR mechanism (Umar et al, 1998). Approximately 25%
of sporadic colon tumours, as well as a number of tumours of
endometrium, ovary and some other organs and tissues, are
deficient in MMR (Peltoma ¨ki, 2003). Moreover, germline muta-
tions in MMR genes predispose to hereditary nonpolyposis
colorectal cancer (HNPCC) syndrome/Lynch syndrome. To date,
659 MLH1 (44% of all identified MMR gene variations), 595 MSH2
(39%), 216 MSH6 (14%) and 45 PMS2 (3%) germline variations
have been reported in the database (Woods et al, 2007; http://
www.med.mun.ca/MMRvariants/). However, no HNPCC pre-
disposing MSH3 mutations have yet been identified.
MMR-deficient tumours are strongly associated with micro-
satellite instability (MSI) (Aaltonen et al, 1993). However, the
degree and type of MSI differ from high to low and between mono-,
di-, tri- and tetranucleotide instability or elevated microsatellite
alterations at selected tetranucleotide repeats (EMAST) (Peltoma ¨ki
and Vasen, 2004; Plaschke et al, 2004; Haugen et al, 2008)
depending on the MMR gene affected. MLH1- and MSH2-deficient
tumours are characterised by both mono- and dinucleotide repeat
instability, whereas the level of MSI is lower in MSH6-deficient
tumours (Bhattacharyya et al, 1995; Papadopoulos et al, 1995).
MSH6-deficient cells are unable to repair single base mismatches,
whereas they retain proficiency to repair two, three and four base
loops (Drummond et al, 1995; Risinger et al, 1996; Umar et al,
1997), thus, causing only mononucleotide repeat instability in
tumours (Wagner et al, 2001; Plaschke et al, 2004). Recently,
EMAST and also low dinucleotide repeat instability have been
associated with MSH3 deficiency both in tumour cell lines and in
sporadic colorectal tumours (Haugen et al, 2008).
The type of MSI seems to be dependent on the substrate
specificities of the MMR protein affected. In human cells, the MMR
process is initiated by the binding of the mismatch recognition
factor MutSa or MutSb to the mispair, followed by the initiation of
the assembly of the repairosome by MutLa (Constantin et al, 2005;
Zhang et al, 2005). MutSb has a high binding affinity to IDLs but,
in contrast, a very low affinity to simple base/base mispairs
(Acharya et al, 1996; Palombo et al, 1996), whereas MutSa has been
shown to bind and repair both base/base mispairs and IDLs
(Drummond et al, 1995; Palombo et al, 1996). Lesion specificity is
believed to lie within the MSH3/MSH6-specific sequences, which
differ notably (Owen et al, 2009). The process through which
ADP–ATP exchange occurs on MSH2 seems to be dependent on
the protein it forms a complex with; MSH6 requires ATP
stabilisation, whereas MSH3 requires ATP hydrolysis, both of
which are dependent on specific lesion binding (Owen et al, 2009).
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ties of these MMR proteins do not yet prove their functional ability
to repair the bound mismatches (Ou et al, 2007).
In this study, we applied the in vitro MMR assay to analyse the
substrate specificities and functionality of MutSa and MutSb using
substrates, GT, IDL1 and IDL2 in three different cell lines. The
in vitro MMR assay allows the functional analysis of all different
MMR protein complexes and all kinds of missense variations in
individual genes in a homologous human MMR system. In this
study, the assay was for the first time applied to test the
interference of an MSH3 variation with repair efficiency.
MATERIALS AND METHODS
Cell lines and nuclear extracts
Cancer cell lines HeLa, LoVo, HCT116 (American Type Culture
Collection, Manassas, VA, USA) and GP5d (European Collection of
Cell Cultures, Salisbury, UK) were cultured according to instruc-
tions of manufacturers. HeLa cells are MMR proficient, whereas
HCT116, LoVo and GP5d cells are MMR deficient. HCT116 cells
lack MLH1 and MSH3 (MSH3 is mutated as a consequence of the
primary MMR defect) (Cannavo et al, 2005), whereas in LoVo cells,
the MSH2 gene is inactivated causing a deficiency of MSH2, MSH3
and MSH6 proteins (Drummond et al, 1997). The lack of MSH2
has been associated with the proteolytic degradation of its
counterparts MSH3 and MSH6 (Cannavo et al, 2005). GP5d cells
are MMR deficient because of primary alterations in MSH2 and
MLH3, resulting in lack of MSH6 and MSH3 proteins as well
(Cannavo et al, 2005; di Pietro et al, 2005).
Nuclear proteins were extracted as described earlier (Lahue et al,
1989; Holmes et al, 1990). Approximately 2–10 10
8 cells were
collected and treated with 30–40ml of cold isotonic buffer (20mM
Hepes pH 7.5, 5mM KCl, 1.5mM MgCl, 250mM sucrose, 0.2mM
PMSF, 1  complete EDTA-free protease inhibitor mixture (Roche
Diagnostics GmbH, Mannheim, Germany), 0.25mgml
 1 aprotinin,
0.7mgml
 1 pepstatin, 0.5mgml
 1 leupeptin, 1mM DTT). The cells
were resuspended in cold hypotonic buffer (isotonic buffer without
sucrose) followed by immediate pelleting. Approximately 1ml per
1–2 10
8 cells of hypotonic buffer was used to disrupt the cell
membranes with a syringe and a narrow-gauge needle. Nuclei were
collected by centrifugation and suspended in cold extraction buffer
(25mM Hepes pH 7.5, 10% sucrose, 1mM PMSF, 0.5mM DTT,
1mgml
 1 leupeptin) and NaCl up to 155mM by rotation in þ41C
for 1h. The supernatant was dialysed for 2h against cold dialysis
buffer (25mM Hepes pH 7.5, 50mM KCl, 0.1mM EDTA pH 8, 10%
sucrose, 1mM PMSF, 2mM DTT, 1mgml
 1 leupeptine) and
collected after further centrifugation.
Preparation of heteroduplex molecules
The heteroduplex DNA molecule is a circular 3193bp long
molecule with a single-strand nick 445bp upstream from the site
of the mismatch. Three different heteroduplex constructs were
prepared; a G–T mismatch (50GT), and a single and two nucleotide
IDLs (50IDL1, 50IDL2). Site-directed mutagenesis was carried out
according to manufacturer’s instructions (QuickChance Site-
directed mutagenesis, Stratagene, La Jolla, CA, USA) to create
the 1nt (delA) and 2nt (delAT) deletions to the positive pGEM
IDL40 plasmid strand at the BglII restriction site. The GT
mismatch was created by replacing adenine with guanine
maintaining a thymine on the complementary strand. Single-
stranded DNA was prepared by infecting pGEM IDL40 trans-
formed XL1-blue bacteria cells with the M13K07 bacteriophage
(Amersham Biosciences, Piscataway, NJ, USA), which replicates
the antisense strand. Single-stranded DNA was extracted from the
bacteriophages and used in excess to re-anneal with the linearised
plasmid DNA creating heteroduplex molecules. Plasmid-safe
DNAse and BND cellulose treatments were carried out to purify
the final product.
Production of wild-type heterodimer protein complexes
Spodoptera frugiperda (Sf9) (Invitrogen, Carlsbad, CA, USA) insect
cells were transfected with bacmid DNA carrying wild-type (WT)
MSH2, MSH3, MSH6, PMS2 or MLH1 cDNA fragments. The cells
were then re-infected to obtain a higher yield of recombinant
baculoviruses (Nystro ¨m-Lahti et al, 2002). WT-recombinant
baculoviruses were used to co-infect Sf9 cells for protein
production forming the heterodimer complexes assayed: MutLa
(MLH1þPMS2), MutSa (MSH2þMSH6) and MutSb (MSH2þ
MSH3). The heterodimeric complexes were extracted as total
protein extracts (TE) at 50h (MutLa) or 72h (MutSa and MutSb)
as described earlier (Kariola et al, 2002; Nystro ¨m-Lahti et al, 2002;
Raevaara et al, 2004; Ollila et al, 2006).
MSH3 mutagenesis
The MSH3 missense mutation (c.2386 C4T, RefSeq NM 002439.2)
was constructed with a PCR-based site-directed mutagenesis kit
according to manufacturer’s instructions (QuickChance Site-
directed mutagenesis, Stratagene) substituting arginine with
tryptophan in codon 796 (p.R796W). The mutated MSH3 cDNA
was introduced into a pFastBac1 vector (Invitrogen) and
sequenced (ABIPrism 3100 Genetic Analyzer; Applied Biosystems,
Foster City, CA, USA). The primer sequences and PCR parameters
are available on request. Proteins were produced and extracted
from Sf9 cells as described in the previous paragraph.
Western blot analysis
Protein expression levels in the nuclear extracts (NEs) were
studied by western blot analysis using 50mg of NE and 0.1–5mlo f
WT-TE by means of sodium dodecyl sulphate polyacrylamide gel
electrophoresis. The proteins were blotted into nitrocellulose
membranes (Hypond, PVDF, Amersham Pharmacia Biotech,
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Figure 1 Western blot analysis of the MMR protein contents in the NEs
used in the functional assay. HeLa, a positive control, includes all five MMR
proteins, MLH1, PMS2, MSH2, MSH3 and MSH6. HCT116 lacks MLH1,
PMS2 and MSH3. Both GP5d and LoVo lack MSH2, MSH3 and MSH6. As
an assay control, Sf9 TE are included with and without the overexpressed
WT MMR proteins. The loading control, a-tubulin is not shown.
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sUppsala, Sweden), which were subsequently incubated with
monoclonal antibodies anti-MSH2 (Calbiochem, San Diego, CA,
USA, MSH2-Ab1, NA-26, 0.2mgml
 1), anti-MSH3 (BD Transduction
Laboratories, Lexington, KY, USA, M94120, 250mgml
 1), anti-
MSH6 (BD Transduction Laboratories, clone 44, 0.02mgml
 1),
anti-PMS2 (Calbiochem/Oncogene Research, San Diego, CA, USA,
Ab-1, 0.2mgml
 1) and anti-MLH1 (BD Biosciences/Pharmingen,
San Diego, CA, USA, clone 168-15, 0.5mgml
 1). Ubiquitously
expressed a-tubulin was used as a loading control to estimate the
MMR protein levels in the extracts (anti-a-tubulin; Sigma, Louis,
MO, USA, DM1A, 0.2mgml
 1).
The in vitro MMR assay
The roles of MutSa-WT and MutSb-WT in 50GT/50IDL1/50IDL2
repair were analysed by an in vitro MMR assay as described earlier
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LoVo +
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MutS 
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MutL  +
MutS 
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GP5d +
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MutS  +
MutS 
HCT116
+MutL 
16 ± 8 18 ± 9 13 ± 4 27 ± 17 31 ± 21 17 ± 17 38 ± 5 1 ± 0 12 ± 5 16 ± 2
10 ± 2 2 ± 2 23 ± 8 40 ± 7 1 ± 0 39 ± 2 44 ± 18 1 ± 0 44 ± 18 19 ± 6
8 ± 5 1 ± 0 17 ± 6 23 ± 10 1 ± 0 26 ± 9 54 ± 4 1 ± 0 48 ± 2 22 ± 6
Figure 2 MMR efficiency of HCT116, LoVo and GP5d NEs complemented with MutSa, MutSb and MutLa complexes for 50GT, 50IDL1 and 50IDL2
substrates. (A) Mock represents heteroduplex only, with no added NE or recombinant protein. MMR-proficient HeLa NE including all five MMR proteins is
used as a positive control. MMR-deficient HCT116, LoVo and GP5d NEs and NEs complemented with Sf9 insect cell TE are used as negative controls. The
top fragment (3193bp) represents the unrepaired linearised heteroduplexes and the two lower fragments (1833 and 1360bp) show the migration of the
repaired and double-digested DNA molecules. The repair percentages (R%) represent fractions of repaired DNA calculated as a ratio of double-digested
DNA relative to total DNA added to the reaction. Values are a mean of three independent experiments. (B) The comparison of substrate-specific repair
efficiencies of the MMR protein complexes (repair efficiency R% and s.d.±%). MutSa is able to repair all three substrates (50GT/50IDL1/50IDL2), whereas
MutSb does not repair 50GT or 50IDL1 in any extracts. However, complementation of HCT116 NE (lacking MLH1, PMS2 and MSH3) with MutLa alone
yields a considerably lower IDL2 repair percentage (12%, s.d.±5%) than after co-complementation with MutLa and MutSb (38%, s.d.±5%). Moreover,
complementation of LoVo and GP5d NEs (lacking MSH2, MSH3 and MSH6) with MutSa yields lower IDL2 repair percentages, 17% (s.d.±17%) and 13%
(s.d.±4%), than when complemented with MutSb, 31% (s.d.±21%) and 18% (s.d.±9%), respectively.
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include 75–100mg of MMR-deficient NE (HCT116, LoVo or GP5d),
or an equal amount of MMR-proficient HeLa extract. The excess
amount of the heteroduplex DNA substrate (50GT, 50IDL1 or 50IDL2)
was set to 100ng. The functionality of WT-proteins was assayed by
complementing HCT116, LoVo and GP5d NEs with an appropriate
amount of Sf9 total extract including the overexpressed MutLa-WT
(50ng), MutSa-WT (200ng) or MutSb-WT (600ng). The amount of
WT-protein in the reaction was titrated to obtain maximum repair
efficiency in each cell line. Owing to the low PMS2 expression, GP5d
NE was complemented with MutLa-WT in each reaction (Figure 1).
MMR-proficient HeLa NE was used as a positive control, whereas
uncomplemented NEs as well as extracts complemented with
untransfected Sf9 proteins were used as negative controls. The
substrates were linearised with Eco31Ir e s t r i c t i o ne n z y m e .A st h e
repair reaction converts a GT heteroduplex to an AT homoduplex or
fills the 1 or 2nt loop structures recreating the BglII restriction site,
the repair efficiency can be measured by the efficiency of the double
restriction. The functionality of mutated MSH3 TE was studied
using 50IDL2 substrate and GP5d NE. Repair percentages were
analysed using Image-Pro 4.0 (Media Cybernetics, Silver Spring,
MD, USA) and calculated as an average of three independent
experiments. Statistical t-test analysis was carried out to evaluate the
significance of the percentage differences observed between MutSa
and MutSb in IDL2 repair.
RESULTS
MMR protein contents of the cell lines used in the in vitro
MMR assay
Western blot analysis was used to characterise the MMR protein
contents in the cell lines used in the functional assay. The analysis
confirmed the absence of MSH2, MSH6 and MSH3 in both LoVo and
GP5d NEs, thus making them suitable for substrate specificity and
functionality studies of MutSa and MutSb (Figure 1). Owing to the
significantly reduced level of PMS2 in GP5d NE, together with the
MutS complex, it was complemented with MutLa-WT. HCT116 NE
was shown to express only MSH6 and MSH2 presenting an
opportunity to study the substrate specificity and repair efficiency of
MutSb (MSH3) and MutLa. The presence of all five MMR proteins in
HeLa NE establishes its aptitude for functioning as a positive control.
The in vitro MMR assay elucidates the substrate
specificities and repair efficiencies of MutSa and MutSb
With the right selection of cell lines, the in vitro MMR assay allows
the functional analysis of all different MMR protein complexes in a
homologous human MMR system. Here, three different substrates,
50GT, 50IDL1 and 50IDL2 were used to study the substrate
specificities and repair efficiencies of MutSa and MutSb.I n
contrast with MutLa, the presence of which is known to be vital for
all these substrates, the type of MutS complex required for optimal
repair efficiency is determined by the substrate construct. The
MMR assay with LoVo, GP5d and HCT116, with various
combinations of natural or complemented MutLa demonstrated
that the role of MutSa is evident in the repair of 50GT and 50IDL1,
whereas the repair of dinucleotide loops requires MutSb for
efficient repair (Figure 2). Remarkably, all three cell lines
demonstrate more efficient dinucleotide repair with MutSb than
with MutSa. In HCT116, the mean repair efficiency was 26% higher
with MutSb than with MutSa (P¼0.0014), in LoVo it was 14%
higher (P¼0.284) and in GP5d 5% higher (P¼0.230).
The functional analysis of an MSH3 variation
The in vitro MMR assay allows the functional analysis of all kinds
of missense variations of the five different MMR genes. The strong
role of MutSb (MSH2þMSH3) in dinucleotide loop repair and the
use of LoVo and GP5d NEs, which lack both MutSa and MutSb,
allow the functional analysis of MSH3 variations in a manner
excluding false positives resulting from the presence of MutSa.I n
this study, for the first time, the assay was applied to test the effect
of an MSH3 variation (MSH3-R796W) on its repair efficiency. The
variation was found in a putative HNPCC family (unpublished).
Our result suggests that the mutated MSH3-R796W protein is
proficient with repair percentages of MSH3-WT 20% (s.d.±5%)
and MSH3-R796W 18% (s.d.±8%) (P¼0.358) (Figure 3).
DISCUSSION
Using different substrate structures, the in vitro MMR assay is able
to demonstrate differences in substrate specificities as well as in
repair efficiencies of MutSa and MutSb. The overlapping roles of
these heterodimeric complexes have been reported earlier
(Acharya et al, 1996; Genschel et al, 1998) generally emphasising
the role of MutSa predominantly for the recognition of base/base
mispairs and small IDLs and MutSb for the recognition of larger
(42bp) IDLs (Acharya et al, 1996; Palombo et al, 1996). Our
experiments support the functional redundancy but contradictory
to the previous impression, in this study, the repair efficiency of
MutSb was shown to exceed that of MutSa in the repair of
dinucleotide loop structures.
The lack of a functional MMR mechanism causes MSI. HCT116
cells, which are deficient in MLH1 and MSH3, complemented with
MLH1 through the addition of chromosome 3 have been shown to
demonstrate mononucleotide repeat stability but still a low level of
dinucleotide and a high level of tetranucleotide repeat instability
suggesting a problem in MSH3. Although, the tetranucleotide
repeat markers represented a level of instability five times higher
than dinucleotide repeats supporting the functional overlap of
MutSb and MutSa in IDL2 repair, low dinucleotide repeat
instability was caused by defected MutSb (MSH3) (Haugen et al,
2008). The microsatellite stability was indeed reversible by
complementing HCT116 cells with both chromosomes 3 and 5,
hence expressing both lost proteins MLH1 and MSH3 (Haugen
et al, 2008). In this study, MutSb not only participated in IDL2
repair but exceeded the repair efficiency of MutSa proven in three
different cell lines, HCT116, LoVo and GP5d. Although, HCT116
expressed a sufficient amount of MutSa to repair GT and IDL1
mismatches, the repair efficiency of IDL2 increased three-fold
when the cells were complemented with MutSb. An increase in
repair efficiencies was also seen in LoVo and GP5d cells when
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Figure 3 The functional analysis of MSH3-R796W. Both MutSb-WT
(20%, s.d.±5%) and MutSb-R796W (18%, s.d.±8%) restore the repair
capability of GP5dþMutLa. The values indicated are averages obtained
from three separate experiments.
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between MutSa and MutSb were not statistically significant as in
HCT116.
By selecting a cell line that lacks the analysed MMR protein, the
in vitro MMR assay allows the functional analysis of all different
MMR proteins and any missense mutation in an individual MMR
gene. The assay has been applied earlier to a large number of
MSH2/6 and MLH1 mutations using GT and IDL1 as target
substrates (Nystro ¨m-Lahti et al, 2002; Kariola et al, 2004; Raevaara
et al, 2005; Ollila et al, 2006). In this study, the finding of the
strong role of MutSb (MSH2þMSH3) in IDL2 repair enables
efficient testing of MSH3 variations. By selecting LoVo and GP5d
NEs, which lack both MutSa and MutSb, the assay was adapted to
study the functional significance of an MSH3 variation for the first
time. Although the analysed variant was shown to be proficient in
IDL2 repair, the assay itself functioned well suggesting its utility
for further MSH3 testing.
In cancer diagnostics, the MSI phenotype has been a hallmark of
HNPCC tumours. However, the levels have varied from high to low
or to no MSI and between mono-, di-, tri- and tetranucleotide
repeat instability dependent on the MMR gene affected and its
substrate specificities. Generally, the MSI marker panel used in the
diagnostics includes mono- and dinucleotide markers, and in MSI-
positive cases, MLH1, MSH2 and MSH6 genes associated with
mono- and dinucleotide repeat instability are analysed for
mutations. Our results are clinically relevant emphasising the
importance of MSH3 in dinucleotide loop repair and we encourage
performing MSH3 mutation analysis when a tumour shows
dinucleotide but no mononucleotide repeat instability.
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